The anti-melanogenesis effect of ligustroside derived from Ligustrum japonicum and its underlying mechanisms are explored.

Vividion Therapeutics, Inc. (Vividion) today announced that the first patient has been dosed in a Phase I clinical trial ...

The abstracts will be available on the AACR 2025 meeting website. The posters will be available online at Erasca.com/science/presentations following the presentations.

These two genes are part of the MAPK signalling pathway, which, in cancer, is rewired for uncontrolled growth. Targeting two different critical points in the same domino chain helps slow or stop ...

The firm believes VVD-159642 has the potential to treat a broad patient population, including those with RAS- and HER2-overexpressed tumors.

In NF1, many of these medications work by blocking a specific cell signaling pathway called Ras/MAPK that is hyperactive in cells that have lost NF1 function due to gene mutation. When this signaling ...